Basonuclin 1 (BNC1)

Basonuclin 1 (BNC1) is a zinc finger transcription factor that is predominantly expressed in the basal layer of the epidermis and in the germ cells of the ovary and testis [UniProt: Q01954]. It functions as a unique regulator of both RNA polymerase I and RNA polymerase II, playing a vital role in the proliferation of keratinocytes and the early stages of germ cell development [NCBI Gene: 646]. BNC1 is critical for maintaining the proliferative capacity of basal keratinocytes and ensuring the proper progression of oogenesis and spermatogenesis. Clinically, mutations in the BNC1 gene are associated with premature ovarian failure (POF16) and certain forms of hereditary corneal dystrophy [PubMed: 24651032]. In oncology, BNC1 is frequently characterized as a tumor suppressor; its gene is often silenced by promoter hypermethylation in various malignancies, including pancreatic and prostate cancer, making it a significant potential epigenetic biomarker for early detection [PubMed: 25135337]. While it is a key biological regulator and a marker for disease progression, there are currently no pharmacological agents that directly target Basonuclin 1 for therapeutic use.

Other names

BNCZinc finger protein basonuclin-1Basonuclin-1HsT19447

There are currently no approved drugs or clinical-stage compounds that directly target Basonuclin 1; however, research focuses on restoring its expression in cases of epigenetic silencing or using its methylation status as a diagnostic indicator.